Integrated DNA Technologies and Aldevron

Your partners for comprehensive genomic medicine workflows

Over 25 years of combined experience in enabling genomic medicine developers to progress from translational research into the clinic.

Seamless purchasing to accelerate timelines to the clinic while streamlining logistics and providing support in all phases of your journey.

End-to-end workflows for your therapeutic gene editing needs from research grade to CGMP manufacturing, off-target safety services, and regulatory support.

Proven solutions, backed by Danaher and scientific collaborations (i.e. Danaher-IGI Beacon for CRISPR Cures) to cover all phases of your complex gene editing needs.

Celebrating combined success in genomic medicine innovation and manufacturing

Integrated DNA Technologies (IDT) and Aldevron have partnered to offer a single-vendor solution that provides high-quality, consistent gene editing tools to support your transition from concept to clinic. By working with a single vendor, you can accelerate your therapy development through a streamlined supply chain, reducing risk and cost, while also leveraging our experienced regulatory teams to support your submissions. Combined, IDT and Aldevron have 20 INDs approved, 18 DMF references, and more than 200 patents.

On-demand webinar

CRISPR genome editing solutions: From discovery to clinical applications

Learn more about the latest advancements and strategies in CRISPR technology. Whether you're in the early stages of research or moving toward clinical applications, gain valuable insights to accelerate your gene editing program.

Watch here

Therapeutic CRISPR gene editing solutions for your modality

Ribonucleoprotein (RNP) workflow

1. Components / A la carte



2. Drug substance (RNP) aldevron

mRNA workflow



3. Drug product aldevron

End-to-end workflows to rapidly drive CRISPR therapeutics into the clinic

Based on the modality of your choice, combined solutions from IDT and Aldevron enable all types of gene editing, including prime and base editing, knock-in, and knock-out. Additionally, experience enhanced editing with Nanoplasmid™ vectors. As an HDR template, Nanoplasmid vectors offer improved HDR knock-in efficiency, yielding twice as many edited cells compared to pUC-based plasmids and three times as many compared to linear dsDNA.

We invite you to explore the below solutions from IDT and Aldevron that will enable you to accelerate to the clinic.

	Discovery/R&D	Pre-clinical	Phases 1-3
IDT™ INTEGRATED DNA TECHNOLOGIES	• Alt-R™ CRISPR gRNA, proteins, enhancers • Alt-R HDR donor oligos and blocks • CRISPR Off-target Analysis Services	• Engineering Run gRNA • CRISPR Off-target Analysis Services • IND/CTA Regulatory Support Services	• CGMP gRNA • IND/CTA Regulatory Support Services
aldevron™	• Research Grade (RG) Cas9, mRNA, ribonucleoproteins (RNPs)	• RG/CGMP Cas9, mRNA, RNPs	• CGMP Cas9, mRNA, RNPs

Driving innovation in genomic medicine with proven expertise and cutting-edge partnerships

IDT and Aldevron offer over 25 years of combined expertise in genomic medicine. Our solutions support your journey from research to clinical application, providing efficient workflows in therapeutic gene editing and robust regulatory support. With the Danaher-IGI Beacon for CRISPR Cures, we aim to address hundreds of diseases using a unified gene-editing platform. Through our partnership, you can streamline logistics and enhance your gene editing processes with proven manufacturing capabilities and expedited timelines. Together, we aim to drive innovation and deliver impactful results in genomic medicine.